Influenza vaccination

M. A. Riddiough, J. E. Sisk and J. C. Bell

Cost-effectiveness analysis was used to evaluate influenza vaccination. From 1971-1972 through 1977-1978, vaccination of an elderly person 65 years of age or older saved net medical care costs while improving health. Vaccination of younger high-risk adults aged 15 through 64 years also improved health for a low net cost per year of healthy life gained. By covering influenza vaccination during those years, the Medicare program would have incurred a net cost for each vaccination of $13 per year of healthy life gained for medical costs connected with influenza and $791 per year gained including costs of treating other illnesses in later life. The analysis indicates the need for epidemiologic research on the extent of influenza and the mechanism of its spread. The results also raise the issue of public policy to promote influenza vaccination among high-risk persons as a low-cost, preventive technology.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevention of Influenza: Recommendations for Influenza Immunization of Children, 2007-2008
Committee on Infectious Diseases
Pediatrics 2008;121:e1016-e1031.
ABSTRACT | FULL TEXT  

Acute Respiratory Illness in Patients With COPD and the Effectiveness of Influenza Vaccination: A Randomized Controlled Study
Wongsurakiat et al.
Chest 2004;125:2011-2020.
ABSTRACT | FULL TEXT  

Recommendations for Influenza Immunization of Children
Committee on Infectious Diseases
Pediatrics 2004;113:1441-1447.
ABSTRACT | FULL TEXT  

Influenza and Cardiovascular Disease: A New Opportunity for Prevention and the Need for Further Studies
Madjid et al.
Circulation 2003;108:2730-2736.
FULL TEXT  

Technical Report: Reduction of the Influenza Burden in Children
Rennels et al.
Pediatrics 2002;110:e80-e80.
ABSTRACT | FULL TEXT  

Reduction of the Influenza Burden in Children
Committee on Infectious Diseases
Pediatrics 2002;110:1246-1252.
ABSTRACT | FULL TEXT  

Oral Administration of Influenza Vaccine in Combination with the Adjuvants LT-K63 and LT-R72 Induces Potent Immune Responses Comparable to or Stronger than Traditional Intramuscular Immunization
Barackman et al.
CVI 2001;8:652-657.
ABSTRACT | FULL TEXT  

Ethics and Immunization Policy: Promoting Dialogue to Sustain Consensus
Feudtner and Marcuse
Pediatrics 2001;107:1158-1164.
ABSTRACT | FULL TEXT  

Cost-Benefit Analysis of a Strategy to Vaccinate Healthy Working Adults Against Influenza
Nichol
Arch Intern Med 2001;161:749-759.
ABSTRACT | FULL TEXT  

Influenza Vaccine for Healthy Working Adults
Nichol et al.
JAMA 2001;285:290-292.
FULL TEXT  

Intranasal Immunization of Mice with Influenza Vaccine in Combination with the Adjuvant LT-R72 Induces Potent Mucosal and Serum Immunity Which Is Stronger than That with Traditional Intramuscular Immunization
Barackman et al.
Infect. Immun. 1999;67:4276-4279.
ABSTRACT | FULL TEXT  

Effectiveness of Live, Attenuated Intranasal Influenza Virus Vaccine in Healthy, Working Adults: A Randomized Controlled Trial
Nichol et al.
JAMA 1999;282:137-144.
ABSTRACT | FULL TEXT  

Meta-Analysis of Effectiveness of Interventions to Increase Influenza Immunization Rates among High-Risk Population Groups
Sarnoff and Rundall
Med Care Res Rev 1998;55:432-456.
ABSTRACT  

Benefits of Influenza Vaccination for Low-, Intermediate-, and High-Risk Senior Citizens
Nichol et al.
Arch Intern Med 1998;158:1769-1776.
ABSTRACT | FULL TEXT  

The Effectiveness of Vaccination against Influenza in Healthy, Working Adults
Nichol et al.
NEJM 1995;333:889-893.
ABSTRACT | FULL TEXT  

The Efficacy and Cost Effectiveness of Vaccination against Influenza among Elderly Persons Living in the Community
Nichol et al.
NEJM 1994;331:778-784.
ABSTRACT | FULL TEXT